First-line treatment with olaparib for early stage BRCA-positive ovarian cancer: May it be possible? Hypothesis potentially generating a line of research
01 Pubblicazione su rivista
Tomao F., Boccia S. M., Chirra M., Palaia I., Petrella M. C., Di Donato V., Colombo N., Panici P. B., Sassu C. M.
DOI: 10.2147/CMAR.S194874
ISSN: 1179-1322
Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.